These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 15889137)

  • 1. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer.
    Wang L; Cao O; Swalm B; Dobrzynski E; Mingozzi F; Herzog RW
    Gene Ther; 2005 Oct; 12(19):1453-64. PubMed ID: 15889137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.
    Fields PA; Kowalczyk DW; Arruda VR; Armstrong E; McCleland ML; Hagstrom JN; Pasi KJ; Ertl HC; Herzog RW; High KA
    Mol Ther; 2000 Mar; 1(3):225-35. PubMed ID: 10933938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.
    Fields PA; Arruda VR; Armstrong E; Chu K; Mingozzi F; Hagstrom JN; Herzog RW; High KA
    Mol Ther; 2001 Sep; 4(3):201-10. PubMed ID: 11545610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Technology evaluation: AAV factor IX gene therapy, Avigen Inc.
    Fabb SA; Dickson JG
    Curr Opin Mol Ther; 2000 Oct; 2(5):601-6. PubMed ID: 11249763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.
    Kay MA; Manno CS; Ragni MV; Larson PJ; Couto LB; McClelland A; Glader B; Chew AJ; Tai SJ; Herzog RW; Arruda V; Johnson F; Scallan C; Skarsgard E; Flake AW; High KA
    Nat Genet; 2000 Mar; 24(3):257-61. PubMed ID: 10700178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.
    High KA
    Trans Am Clin Climatol Assoc; 2003; 114():337-51; discussion 351-2. PubMed ID: 12813929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects.
    Hasbrouck NC; High KA
    Gene Ther; 2008 Jun; 15(11):870-5. PubMed ID: 18432276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy.
    Herzog RW; Fields PA; Arruda VR; Brubaker JO; Armstrong E; McClintock D; Bellinger DA; Couto LB; Nichols TC; High KA
    Hum Gene Ther; 2002 Jul; 13(11):1281-91. PubMed ID: 12162811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Muscle as a target for supplementary factor IX gene transfer.
    Hoffman BE; Dobrzynski E; Wang L; Hirao L; Mingozzi F; Cao O; Herzog RW
    Hum Gene Ther; 2007 Jul; 18(7):603-13. PubMed ID: 17594244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.
    Herzog RW; Mount JD; Arruda VR; High KA; Lothrop CD
    Mol Ther; 2001 Sep; 4(3):192-200. PubMed ID: 11545609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products.
    Yuasa K; Yoshimura M; Urasawa N; Ohshima S; Howell JM; Nakamura A; Hijikata T; Miyagoe-Suzuki Y; Takeda S
    Gene Ther; 2007 Sep; 14(17):1249-60. PubMed ID: 17581597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent expression of canine factor IX in hemophilia B canines.
    Chao H; Samulski R; Bellinger D; Monahan P; Nichols T; Walsh C
    Gene Ther; 1999 Oct; 6(10):1695-704. PubMed ID: 10516718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product.
    Yuasa K; Sakamoto M; Miyagoe-Suzuki Y; Tanouchi A; Yamamoto H; Li J; Chamberlain JS; Xiao X; Takeda S
    Gene Ther; 2002 Dec; 9(23):1576-88. PubMed ID: 12424610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice.
    Petry H; Brooks A; Orme A; Wang P; Liu P; Xie J; Kretschmer P; Qian HS; Hermiston TW; Harkins RN
    Gene Ther; 2008 Jan; 15(1):54-60. PubMed ID: 17960164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF.IX gene therapy.
    Chen J; Wu Q; Yang P; Hsu HC; Mountz JD
    Mol Ther; 2006 Feb; 13(2):260-9. PubMed ID: 16324888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.
    Manno CS; Pierce GF; Arruda VR; Glader B; Ragni M; Rasko JJ; Ozelo MC; Hoots K; Blatt P; Konkle B; Dake M; Kaye R; Razavi M; Zajko A; Zehnder J; Rustagi PK; Nakai H; Chew A; Leonard D; Wright JF; Lessard RR; Sommer JM; Tigges M; Sabatino D; Luk A; Jiang H; Mingozzi F; Couto L; Ertl HC; High KA; Kay MA
    Nat Med; 2006 Mar; 12(3):342-7. PubMed ID: 16474400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
    Snyder RO; Miao CH; Patijn GA; Spratt SK; Danos O; Nagy D; Gown AM; Winther B; Meuse L; Cohen LK; Thompson AR; Kay MA
    Nat Genet; 1997 Jul; 16(3):270-6. PubMed ID: 9207793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice.
    Rivière C; Danos O; Douar AM
    Gene Ther; 2006 Sep; 13(17):1300-8. PubMed ID: 16688207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice.
    Fields PA; Armstrong E; Hagstrom JN; Arruda VR; Murphy ML; Farrell JP; High KA; Herzog RW
    Gene Ther; 2001 Mar; 8(5):354-61. PubMed ID: 11313811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic levels of factor IX expression using a muscle-specific promoter and adeno-associated virus serotype 1 vector.
    Liu YL; Mingozzi F; Rodriguéz-Colôn SM; Joseph S; Dobrzynski E; Suzuki T; High KA; Herzog RW
    Hum Gene Ther; 2004 Aug; 15(8):783-92. PubMed ID: 15319035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.